Comparative Pharmacology
Head-to-head clinical analysis: SULFACEL 15 versus SULFAIR FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACEL 15 versus SULFAIR FORTE.
SULFACEL-15 vs SULFAIR FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
Folate antagonist; inhibits dihydropteroate synthetase in bacterial folate synthesis pathway.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
1-2 tablets (sulfamethoxazole 400 mg/trimethoprim 80 mg per tablet) orally every 12 hours.
None Documented
None Documented
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment (up to 20-30 hours), necessitating dose adjustment.
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Primarily renal excretion of unchanged drug (approx. 70-80%) and glucuronide conjugates; biliary excretion accounts for less than 20%; fecal elimination minimal.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)